BioNTech’s Bold Leap: Pivoting from Pandemic Profits to Cutting-Edge Cancer Treatments
BioNTech is pivoting from COVID-19 vaccine production to developing innovative mRNA cancer therapies. Despite a decrease in pandemic-era revenues, BioNTech's earnings outperformed market expectations with a Q4 2024 EPS of…